October 24, 2013
Please join Fitch, Even, Tabin & Flannery LLP for a complimentary webinar, “Inter Partes Reviews (IPRs): Lessons from the First Year,” presented by Timothy R. Baumann. The webinar will take place on Thursday, October 24, 2013, at 9:00 am PDT / 10:00 am MDT / 11:00 am CDT / 12:00 noon EDT.
One of the new procedures instituted by the Leahy-Smith America Invents Act (AIA) is the inter partes review (IPR). The IPR is a recently instituted post-issuance procedure before the Patent Trial and Appeal Board that purposefully introduces litigation-type aspects into a patent office setting. Under the terms of the AIA, a determination of the validity of claims of a patent will be reached within one year after an inter partes review is initiated.
During this webinar, we will discuss these IPR topics and more:
- Background information concerning IPRs
- Estoppel consequences of IPRs
- Limited discovery aspects of IPRs
- Motion practice
- Claim amendments
- Parallel litigation considerations such as stays
Our speaker will be Fitch Even partner Timothy R. Baumann. Tim has extensive experience assisting clients in the acquisition, protection, and management of all forms of intellectual property, particularly through complex patent prosecution and through the preparation of infringement and validity opinions, reexamination proceedings, and patent licensing agreements. Tim’s substantial litigation experience includes motion practice, taking and defending depositions, discovery practice, and trial work. At present, Tim is engaged in an active IPR (one of the very first filed).
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more